Work for Syndax Pharmaceuticals Inc?

Claim Your Profile

Syndax Pharmaceuticals Inc Logo Image

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc has reached its limit for report views.

Please check back to see if Syndax Pharmaceuticals Inc has upgraded their profile page to allow their financial information to be viewed. In the meantime, here are a few annual reports from similar companies.

About Syndax Pharmaceuticals Inc

51-200 Employees
Based in Waltham, Massachusetts

Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Company lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer.

Ticker:
SNDX
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
--None-- (See More --None-- Companies)
Sector:
--None-- (See More --None-- Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol